Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $12.9850 (-0.23%) ($12.9850 - $13.1800) on Thu. Feb. 23, 2023. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.39% (three month average) | RSI | 40 | Latest Price | $12.9850(-0.23%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -0.2% a day on average for past five trading days. | Weekly Trend | FOLD advances 0.1% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) XBI(60%) IBB(55%) IWO(45%) IWM(44%) IWC(42%) | Factors Impacting FOLD price | FOLD will decline at least -1.195% in a week (0% probabilities). TBT(-17%) UUP(-10%) VIXM(-9%) BNDX(-6%) BND(-6%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.195% (StdDev 2.39%) | Hourly BBV | 0.4 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $13(-0.12%) | 10 Day Moving Average | $12.85(1.05%) | 20 Day Moving Average | $12.92(0.5%) | To recent high | -3.7% | To recent low | 15.2% | Market Cap | $3.353b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |